The diagnosis of chronic hepatitis C has been considered a relative or absolute contraindication for non-liver transplantation in the past, due to concerns of liver disease progression post-transplantation and a lack of safe and effective therapies. The recent availability of interferon-free, all-oral, antiviral drug combinations to treat of chronic hepatitis C provides an opportunity to revise management algorithms to optimize the care of non-liver transplant candidates and recipients.
Describe the components of the new HCV all-oral combinations, the role of ribavirin, and anticipated rates of HCV eradication with treatment
Summarize the safety data of new HCV therapies as it pertains to non-liver transplant candidates and recipients, including key drug-drug interactions (HCV antivirals and immunosuppressive drugs)
Evaluate the pros and cons of HCV treatment pre versus post-transplantation, including considerations related to use of anti-HCV positive donors